Analysts See $-0.31 EPS for OncoMed Pharmaceuticals, Inc. (OMED)

March 8, 2018 - By Linda Rogers

 Analysts See $ 0.31 EPS for OncoMed Pharmaceuticals, Inc. (OMED)
Investors sentiment increased to 0.71 in Q3 2017. Its up 0.12, from 0.59 in 2017Q2. It is positive, as 12 investors sold OncoMed Pharmaceuticals, Inc. shares while 19 reduced holdings. 7 funds opened positions while 15 raised stakes. 13.02 million shares or 24.21% less from 17.17 million shares in 2017Q2 were reported.
Tudor Invest Et Al holds 0% or 32,049 shares in its portfolio. National Bank & Trust Of New York Mellon holds 23,538 shares or 0% of its portfolio. Glenmede Tru Co Na holds 3,600 shares or 0% of its portfolio. Proshare Advsr Limited Liability owns 21,195 shares or 0% of their US portfolio. Jacobs Levy Equity Mngmt invested in 0% or 41,800 shares. Wells Fargo & Mn invested in 4,490 shares. Alyeska Investment Gp Limited Partnership reported 521,883 shares stake. Cannell Peter B & invested in 303,971 shares or 0.05% of the stock. First Eagle Invest Mgmt Lc, New York-based fund reported 219,420 shares. Schwab Charles Invest Management Incorporated reported 50,729 shares. Geode Mngmt Limited Com stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Perceptive Advsrs owns 1.04 million shares for 0.18% of their portfolio. Primecap Mngmt Ca holds 0.02% or 5.57M shares. 911,184 were accumulated by Ameriprise Finance. Bridgeway Mngmt reported 88,900 shares.

Since October 10, 2017, it had 0 insider buys, and 5 sales for $27,111 activity. $5,295 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) was sold by Patel Sunil. Lewicki John A. had sold 1,248 shares worth $5,295 on Tuesday, October 10. 1,248 OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) shares with value of $5,295 were sold by Hager Alicia J.. The insider Gurney Austin sold 1,248 shares worth $5,295.

Analysts expect OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report $-0.31 EPS on March, 14.They anticipate $0.39 EPS change or 55.71 % from last quarter’s $-0.7 EPS. After having $-0.28 EPS previously, OncoMed Pharmaceuticals, Inc.’s analysts see 10.71 % EPS growth. The stock decreased 0.69% or $0.02 during the last trading session, reaching $2.88. About 188,166 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 70.06% since March 8, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Ratings Coverage

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. OncoMed Pharmaceuticals had 18 analyst reports since September 9, 2015 according to SRatingsIntel. As per Wednesday, September 9, the company rating was initiated by Jefferies. Jefferies maintained it with “Buy” rating and $16 target in Wednesday, August 10 report. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The company was maintained on Thursday, August 24 by Jefferies. The rating was initiated by H.C. Wainwright on Thursday, September 22 with “Buy”. SunTrust maintained it with “Hold” rating and $4.0 target in Friday, October 6 report. The rating was maintained by Mizuho on Tuesday, January 26 with “Buy”. On Tuesday, April 11 the stock rating was downgraded by BMO Capital Markets to “Market Perform”. The stock has “Mkt Perform” rating by Leerink Swann on Monday, January 25. The firm has “Buy” rating given on Monday, April 18 by Cantor Fitzgerald.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $109.03 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: which released: “OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial …” on February 22, 2018, also with their article: “OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence” published on September 19, 2017, published: “OncoMed Announces Chairman, President and Chief Executive Officer Paul J …” on January 04, 2018. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: and their article: “OncoMed Pharmaceuticals’ (OMED) CEO Sunil Patel on Q3 2017 Results – Earnings …” published on November 05, 2017 as well as‘s news article titled: “Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed …” with publication date: January 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.